We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Onyx Pharmaceuticals, Inc. (MM) | NASDAQ:ONXX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 124.70 | 0 | 01:00:00 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Check appropriate box to designate the rule pursuant to which this
Schedule is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
4 CITIZENSHIP OR PLACE OF ORGANIZATION
2'834'452 --------------------------------------------------------- NUMBER OF 6 SHARED VOTING POWER SHARES BENEFICIALLY OWNED BY --------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON WITH --------------------------------------------------------- 8 SHARED DISPOSITIVE POWER |
Item 1.
(a) Name of Issuer: ONYXX PHARMAEUTICALS INC
(b) Address of Issuer's Principal Executive Offices:
2100 Powell Street
Emeryville C.A. 94 608
United States
Item 2.
(a) Name of Person Filing:
PICTET FUNDS - BIOTECH
(b) Address of Principal Business Office or, if none, Residence:
Luxembourg
(c) Citizenship: Luxembourg
(d) Title of Class Securities: Common Stock
(e) CUSIP Number: N.A.
Item 3.
Not applicable.
Item 4. Ownership
(a) Amount Beneficially Owned:
2'834'452
(b) Percent of Class: 4.98%.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
(ii) shared power to vote or to direct the vote:
(iii) sole power to dispose or to direct the disposition of:
(iv) shared power to dispose or to direct the disposition of:
Item 5. Ownership of Five Percent or Less of a Class
**The Reporting Person beneficially owned more than 5 percent of the Common Stock as of May 21st, 2009 but has subsequently decreased its beneficial ownership below 5 percent as of the date of this filing.
Item 6.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
Not Applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of the Group
Not applicable.
Item 10. Certification
By signing below I certify that, to the best if my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquire and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: July 24th, 2009 Charles Vallee Claudy Huart -------------- -------------- -------------- ------------- |
1 Year Onyx Pharmaceuticals, Inc. (MM) Chart |
1 Month Onyx Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions